ArticleRadiology case reports2025
Radiation safety and dialysate analysis in hemodialysis following Lu-177-PSMA-617 therapy: A case report.
Article in Radiology case reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Guideline of guidelines: lutetium-177 PSMA radioligand therapy in advanced prostate cancer.BJU international · 2026Guideline
- Dosimetry of [EJNMMI research · 2026Article
- Use ofWiener klinische Wochenschrift · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: We present a patient who is undergoing regular HD and received Lu-177-PSMA-617 treatment, regarding radiation safety issues including environmental radiation, exposure of medical personnel, and the radioactivity in the dialysate. Methods: A 78 years old man with metastatic castration-resistant prostate cancer undergoing HD received 84.4 mCi (3.1 GBq) of Lu-177-PSMA-617. First HD during the 20th-24th hours after injection, and the second HD during 68th-71st hours. The environmental exposure rate and personnel exposure monitoring were measured. The dialysate was collected and sampled, and the activity was measured. Results: During the first HD session, where dialysate was collected in the room, medical personnels received exposure of 3-19µSv. Dialysate was drained out in the second HD, and medical personnels received 2-4 µSv. The radiation exposure rates in the first HD were measured as follows: 3-4 µSv/hr bedside, 1.2-1.5 µSv/hr at 1 meter, and less than 0.3 µSv/hr at 4 meters. In the second HD, the rates were 2-3 µSv/hr bedside, 1.2-1.8 µSv/hr at 1 meter, and less than 0.3 µSv/hr at 4 meters.The dialysate had an activity of 6.88 mCi (0.25 GBq) in 120 liters of the first HD, while in the second HD, it had 2.13 mCi (0.08 GBq) in 90 liters. Conclusion: For the medical personnel involving HD, the accumulative exposure doses were than 2-19 µSv after 20 hour of injection. The environmental exposure rate would drop to background at 4m away from the patient. The dialysate contained minimal amounts of Lu-177 radioactivity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.